A Study to Evaluate the Safety and Efficacy of Domperidone in Pediatric Participants With Nausea and Vomiting Due to Acute Gastroenteritis

Gastroenteritis Clinical Trial

Official title:

A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group, Prospective Study to Evaluate the Safety and Efficacy of Domperidone in 6-month-old to 12-year-old Pediatric Subjects With Nausea and Vomiting Due to Acute Gastroenteritis

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02699385
• Other study ID #: CR107501
• Secondary ID: R033812GTS300120
• Status: Terminated
• Phase: Phase 3
• Start date: December 7, 2015
• Est. completion date: August 3, 2017

Study information

• Verified date: March 2019
• Source: Janssen-Cilag International NV
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to demonstrate that domperidone suspension plus oral rehydration therapy (ORT) is more effective than placebo plus ORT at reducing the symptoms of vomiting associated with acute gastroenteritis (AG) within the first 48 hours of treatment administration in pediatric participants with AG and mild-to-moderate dehydration.

Description:

This is a randomized (study medication assigned to participants by chance), double-blind (neither the researchers nor the participants know what treatment the participant is receiving), parallel-group, placebo-controlled, multicenter (when more than one hospital or medical school team work on a medical research study) study. The study consists of 3 Phases: Screening Phase (-2 to 0 hours prior to baseline on Day 1), Double-blind treatment Phase (up to 7 Days) and follow-up Phase (7 Days). The duration of participation in the study for each participant is at most 15 Days. Efficacy and safety of domperidone will be evaluated. Participants' safety will be monitored throughout the study.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 10
• Est. completion date: August 3, 2017
• Est. primary completion date: August 3, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Months to 12 Years

Eligibility

Inclusion Criteria:

• The participant presents with at least 3 episodes of non-bilious, non-bloody vomiting within the 24 hours prior to visiting the physician's office. The participant has at least 2 signs and symptoms other than vomiting consistent with acute gastroenteritis (AG) (example, fever, nausea, diarrhea, abdominal pain, bloating, or discomfort) within 3 hours prior to visiting the physician's office

• The participant has mild-to-moderate dehydration

• The participant had at least 1 episode of non-bloody diarrhea within the 24 hours prior to the visiting the physician's office

Exclusion Criteria:

• The participant has severe dehydration or severe malnutrition

• The participant who has vomiting and clinical symptoms for longer than 72 hours prior to the baseline physician's office visit

• The participant needs intravenous (IV) fluid replacement

• The participant has chronic severe diarrhea, a previous history of Helicobacter pylori infection or received treatment for H. pylori-induced gastritis, active peptic ulcer, celiac disease, Crohn's disease, ulcerative colitis, eosinophilic esophagitis, malabsorption, short bowel syndrome, post-viral gastroparesis, cyclic vomiting syndrome, or previous gastrointestinal surgery

• The participant has upper respiratory symptoms such as cough, congestion, otitis media or pharyngitis

Related Conditions & MeSH terms

• Gastroenteritis
• Vomiting

Intervention

Other:
• Oral Rehydration Therapy
Each participants will initiate ORT in the physician's office on Day 1.

Drug:
• Domperidone
Each participants will receive Domperidone 0.25 milligram per killogram (mg/kg) of body weight of oral suspension thrice daily for up to 7 days.
• Placebo
Each participants will receive placebo oral suspension thrice daily for up to 7 days.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Janssen-Cilag International NV

Countries where clinical trial is conducted

Austria,  Belgium,  Russian Federation,  South Africa,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With No Vomiting Episode Within the First 48 Hours of the First Treatment Administration	The vomiting episodes will be recorded for each participants in the eDiary.	48 Hours
Secondary	Percentage of Participants 4 Years of Age or Older Who Have No Episode of Nausea Within the First 48 Hours of the First Treatment Administration	The nausea episodes will be recorded in the eDiary.	48 Hours
Secondary	Number of Vomiting Episodes for Participants Within the 0 to 24 Hour, Greater Than (>) 24 to 48 Hour, and >48 Hour to 7 Day Periods After the First Treatment Administration	The vomiting episodes will be recorded for each participants in the eDiary.	Up to Day 7
Secondary	Number of Episodes of Nausea for Participants 4 Years of Age or Older Within the 0 to 24 Hour, >24 to 48 Hour, and >48 Hour to 7 Day Periods After the First Treatment Administration	The nausea episodes will be recorded in the eDiary.	Up to Day 7
Secondary	Percentage of Participants who Have No Episode of Vomiting Within the 0 to 24 Hour, >24 to 48 Hour, and >48 Hour to 7 Day Periods After the First Treatment Administration	The vomiting episodes will be recorded for each participants in the eDiary.	Up to Day 7
Secondary	Percentage of Participants 4 Years of Age or Older Who Have No Episode of Nausea Within the 0 to 24 Hour, >24 to 48 Hour, and >48 Hour to 7 Day Periods After the First Treatment Administration	The nausea episodes will be recorded in the eDiary.	Up to Day 7
Secondary	Percentage of Participants Who Have No Episode of Vomiting Within the 7 Day Treatment Period After the First Treatment Administration	The vomiting episodes will be recorded for each participants in the eDiary.	Day 7
Secondary	Percentage of Participants 4 Years of Age or Older Who Have No Episode of Nausea Within the 7 Day Treatment Period After the First Treatment Administration	The nausea episodes will be recorded in the eDiary.	Day 7
Secondary	Percentage of Participants Taking a Rescue Medication Within the 7 Day Treatment Period	If nausea, vomiting, or diarrhea worsens during the study and the investigator initiates rescue medication, the study medication will be discontinued.	Day 7
Secondary	Percentage of Participants Stopping Study Medication Early Due to Vomiting-Free for 24 Hours Within the 7 Day Treatment Period	The vomiting episodes will be recorded for each participants in the eDiary.	Day 7
Secondary	Time to Last Study Medication Within the 7 Day Treatment Period	Time taken to administer last study medication will be observed.	Day 7
Secondary	Percentage of Participants Referred to an Emergency Room/Hospital for Treatment Within the 7 Day Treatment Period	If nausea, vomiting, or diarrhea worsens during the study and admits the participant to the hospital for IV fluids, the study medication will be discontinued.	Day 7
Secondary	Time-to-Last Vomiting Within the 7 Day Period After the First Treatment Administration	The vomiting episodes will be recorded for each participants in the eDiary.	Day 7
Secondary	Change From Baseline in Hydration Score at Day 2	The severity of dehydration will be assessed using the Dehydration Score Assessment. a) Children under 24 months of age with a score range 7 to 10 points have mild dehydration and children with a score range of 11 to 17 points have moderate dehydration (only children under 24 months of age are evaluated for tears). b) Children 24 months of age or older with a score range of 6 to 9 points have mild dehydration and children with a score range of 10 to 15 points have moderate dehydration. and c) Children under 24 months of age with scores of 18 or more and children 24 months of age or older with scores of 16 or more are considered to be severely dehydrated and are excluded from the study.	Baseline and Day 2
Secondary	Change From Baseline in Weight at Day 2	Weight will be measured to the nearest 100 grams in underwear (no diaper/nappy/training pants).	Baseline and Day 2
Secondary	Percentage of Participants With Diarrhea Within 0 to 24 Hour, >24 to 48 Hour, >48 Hour to 7 Day, and 0 Hour to 7 Day Periods After the First Successful Treatment Administration	The diarrhea episodes will be recorded for each participant in the eDiary.	Up to Day 7

External Links

•   A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group, Prospective Study to Evaluate the Safety and Efficacy of Domperidone in 6-month-old to 12-year-old Pediatric Subjects With Nausea and Vomiting Due to Acute Gastroenteritis